Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Tofacitinib
Xeljanz
Not routinely available
SMC (SMC2122)
04/12/2024
Indication
For the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response, or were intolerant to conventional therapy or a biologic agent.
Therapeutic Area
Gastro-intestinal system
Status Description
Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines
Formulation
5mg, 10mg film-coated tablets
Comments
-